Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF

The ENVISAGE-TAVI AF trial demonstrated that Edoxaban’s non-inferiority to warfarin with regards to myocardial infarction (MI), ischaemic stroke, systemic thromboembolism, and valve thrombosis, in participants…

View More Highlights from Day 2 of the ESC 2021 congress – ENVISAGE-TAVI AF
Diagnostic pathways for myocardial infarction

Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA)

By Giovanni Occhipinti, Chiara Bucciarelli-Ducci & Davide Capodanno When acute myocardial injury is found in a clinical setting suggestive of myocardial ischaemia, the event is…

View More Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA)
ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement

STEMI after TAVR associated with poorer outcomes.

By Ahmed El-Medany Longer door-to-balloon times and higher percutaneous coronary intervention (PCI) failure rate were observed in a multicentre study by Faroux et al. 118…

View More STEMI after TAVR associated with poorer outcomes.
Image of a heart with myocardial infarction

Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction

By Ahmed El-Medany In a large retrospective study by Venetsanos et al, researchers analysed 37,990 patients from the SWEDEHEART registry with myocardial infarction (MI) who…

View More Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction